Effect of cyproterone acetate in comparison to flutamide and megestrol acetate on the ventral prostate, seminal vesicle, and adrenal glands of adult male rats
- PMID: 2960960
- DOI: 10.1002/pros.2990110408
Effect of cyproterone acetate in comparison to flutamide and megestrol acetate on the ventral prostate, seminal vesicle, and adrenal glands of adult male rats
Abstract
Cyproterone acetate (CPA) has a stronger inhibitory effect than megestrol acetate (MGA) and flutamide (FL) on the prostate and seminal vesicle of intact adult rats. Only in the clinically irrelevant regimen of castration and simultaneous androgen substitution is FL as a competitive androgen antagonist more potent than CPA and MGA. The latter inhibit complete involution of the ventral prostate but not of the seminal vesicle of castrated adult rats. This effect is very small in magnitude, cannot be increased by the use of higher doses, and is only reduced but not blocked by simultaneous treatment with high doses of FL. Further, CPA is unable to stimulate proliferation or restore the function of the involuted rat prostate. CPA and MGA inhibit adrenal weight in rats, thus indicating a glucocorticoidlike activity in this species. A critical review of all available data on the antiandrogenic, glucocorticoidlike, and possible paradoxical androgenlike activities of CPA in different animal experiments has no important bearing on the clinical effectiveness of CPA in the treatment of prostatic cancer.
Similar articles
-
Analysis of the androgenic activity of synthetic "progestins" currently used for the treatment of prostate cancer.J Steroid Biochem. 1987 Oct;28(4):379-84. doi: 10.1016/0022-4731(87)91054-5. J Steroid Biochem. 1987. PMID: 2444770
-
Comparison of the antiandrogenic/androgenic activities of flutamide, cyproterone acetate and megestrol acetate.Mol Cell Endocrinol. 1985 Oct;42(3):283-8. doi: 10.1016/0303-7207(85)90059-0. Mol Cell Endocrinol. 1985. PMID: 3930312
-
Relative effectiveness of alternative androgen withdrawal therapies in initiating regression of rat prostate.J Urol. 1988 Jun;139(6):1337-42. doi: 10.1016/s0022-5347(17)42914-4. J Urol. 1988. PMID: 2967378
-
Mechanism of action and pure antiandrogenic properties of flutamide.Cancer. 1993 Dec 15;72(12 Suppl):3816-27. doi: 10.1002/1097-0142(19931215)72:12+<3816::aid-cncr2820721711>3.0.co;2-3. Cancer. 1993. PMID: 8252497 Review.
-
Flutamide and other antiandrogens in the treatment of advanced prostatic carcinoma.Cancer Treat Res. 1988;39:131-45. doi: 10.1007/978-1-4613-1731-9_9. Cancer Treat Res. 1988. PMID: 2908604 Review.
Cited by
-
Flutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in advanced prostatic cancer.Drugs Aging. 1991 Mar;1(2):104-15. doi: 10.2165/00002512-199101020-00003. Drugs Aging. 1991. PMID: 1794008 Review.
-
Flutamide. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in advanced prostatic cancer.Drugs. 1989 Aug;38(2):185-203. doi: 10.2165/00003495-198938020-00003. Drugs. 1989. PMID: 2670515 Review.
-
Cyproterone. A review of its pharmacology and therapeutic efficacy in prostate cancer.Drugs Aging. 1994 Jul;5(1):59-80. doi: 10.2165/00002512-199405010-00006. Drugs Aging. 1994. PMID: 7919640 Review.
-
The future of antihormone therapy: innovations based on an established principle.J Cancer Res Clin Oncol. 1996;122(7):383-96. doi: 10.1007/BF01212877. J Cancer Res Clin Oncol. 1996. PMID: 8690748 Free PMC article. Review.
-
Growth inhibition of DMBA-induced rat mammary carcinomas by the antiandrogen flutamide.J Cancer Res Clin Oncol. 1995;121(3):150-4. doi: 10.1007/BF01198096. J Cancer Res Clin Oncol. 1995. PMID: 7713986 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources